Table 3.
Parameters of the optimized regression model for anti-S antibodies.
| Characteristic | exp (Beta) | 95% CI1 | p-value |
|---|---|---|---|
| Sampling Interval | 0.75 | 0.65, 0.86 | <0.001 |
| Vaccination | |||
| ChAdOx1s | 18.1 | 1.22, 269 | 0.037 |
| BNT162b2 | 36.0 | 5.51, 235 | <0.001 |
| Gam-COVID | 3.08 | 0.19, 49.9 | 0.4 |
| mRNA-1273 | 71.1 | 8.74, 579 | <0.001 |
| BBIBP-CorV | 0.25 | 0.02, 4.16 | 0.3 |
| Age | 0.96 | 0.93, 0.99 | 0.004 |
| Targeted therapies | |||
| anti-CD20 | 0.03 | 0.00, 0.26 | 0.002 |
| IL-6 inhibitor | 0.26 | 0.07, 0.98 | 0.049 |
| JAK inhibitor | 1.75 | 0.20, 15.2 | 0.6 |
| TNF-α inhibitor | 0.20 | 0.08, 0.49 | <0.001 |
In a patient who is treated with a TNF antagonist the expected anti-S antibody level is 80% smaller (p<0.001) and who is treated with a IL-6 inhibitor the anti-S antibody level is 74% lower (p=0.049). The effect of a CD20 antagonist is very pronounced, anti-S antibody level is only 3% of the corresponding control (p=0.002). In each month the anti-S antibody level decreases by 25% (p<0.001). Each additional age corresponds to a 4 percent decrease in anti-S antibodies (p=0.004).
1CI, Confidence Interval.